• Explore /
  • Poster
  • / Growth factor use in patients with breast cancer treated with docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) regimen: Cost implications in a safety-net system.

Growth factor use in patients with breast cancer treated with docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) regimen: Cost implications in a safety-net system.

Abstract Poster

Authors

null

Sarah Kashanian

UT Southwestern Medical Center, Dallas, TX

Sarah Kashanian, Shifa Kanjwal, Steven Brown, Hsiao Ching Li, Nisha Unni, Glenda Maria Delgado Ramos, Samira K. Syed, Navid Sadeghi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship

Sub Track

Cost and Cost-Effectiveness of Care

Citation

JCO Oncol Pract 19, 2023 (suppl 11; abstr 10)

DOI

10.1200/OP.2023.19.11_suppl.10

Abstract #

10

Poster Bd #

A5

Abstract Disclosures

Similar Posters

First Author: Jaime Shaw

First Author: Katherine Lovat

First Author: Nicholas Patrick McAndrew

First Author: Nely Mercy Diaz Mejia